J&J’s London Innovation Center Inks Four Deals With European Biotechs
This article was originally published in The Pink Sheet Daily
France's Effimune and the Netherland's Merus are among a flurry of European biotechs entering into collaborations with Johnson & Johnson via its London Innovation Center.
You may also be interested in...
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.